Literature DB >> 32246174

The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade.

Isobel S Okoye1, Lai Xu1, John Walker2, Shokrollah Elahi3,4,5,6.   

Abstract

On-treatment steroids for countering immune checkpoint inhibitor-induced inflammatory responses (irAEs) are a hallmark of cancer immunotherapy. However, the suppressive nature of steroids has raised questions regarding their ability to compromise the function of the 'proliferative burst' of effector T cells induced by immune checkpoint antibodies. We investigated the effector functions and the co-inhibitory receptor profile of stimulated peripheral blood mononuclear cells (PBMCs) pre-treated with prednisone and dexamethasone alone or in the presence of anti-PD-1/CTLA-4 antibodies. Also, clinical analysis of a patient who exhibited irAEs following combination (anti-PD-1/CTLA-4) in the presence of glucocorticoids was done. We found that prednisone in contrast to dexamethasone did not compromise T cell cytokine production (IL-2, IFN-γ and TNF-α) and proliferation in the absence or presence of anti-PD-1/CTLA-4 antibodies, when a physiological concentration was used. Neither single prednisone treatment nor co-treatment with checkpoint inhibitors impacted the expression of co-inhibitory receptors PD-1, CTLA-4, TIM-3 and LAG-3. In contrast, dexamethasone treatment promoted downregulation of LAG-3 expression by T cells. In addition, co-treatment of PD-1 + Jurkat cells with prednisone and/or dexamethasone with anti-PD-1 before stimulation significantly reduced SHP-2 phosphorylation, indicative of increased T cell function. Our findings hereby demonstrate a differential steroid effect on T cell function, which should be taken into consideration for patients undergoing immunotherapy. Also, the clinical analysis of a patient who exhibited irAEs following combination (anti-PD-1/CTLA-4) therapy indicated complete metabolic response in the presence of glucocorticoids. Therefore, concomitant use of prednisone does not appear to interfere with the function of immune checkpoint blockade.

Entities:  

Keywords:  Dexamethasone; Immune check points; Prednisone; T cells

Year:  2020        PMID: 32246174     DOI: 10.1007/s00262-020-02555-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  14 in total

1.  The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro.

Authors:  Mario Presti; Marie Christine Wulff Westergaard; Arianna Draghi; Christopher Aled Chamberlain; Aishwarya Gokuldass; Inge Marie Svane; Marco Donia
Journal:  Cancer Immunol Immunother       Date:  2020-11-09       Impact factor: 6.968

2.  Glucocorticoids Bind to SARS-CoV-2 S1 at Multiple Sites Causing Cooperative Inhibition of SARS-CoV-2 S1 Interaction With ACE2.

Authors:  Hassan Sarker; Rashmi Panigrahi; Eugenio Hardy; J N Mark Glover; Shokrollah Elahi; Carlos Fernandez-Patron
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

3.  Erythroid precursors and progenitors suppress adaptive immunity and get invaded by SARS-CoV-2.

Authors:  Shima Shahbaz; Lai Xu; Mohammed Osman; Wendy Sligl; Justin Shields; Michael Joyce; D Lorne Tyrrell; Olaide Oyegbami; Shokrollah Elahi
Journal:  Stem Cell Reports       Date:  2021-05-11       Impact factor: 7.765

Review 4.  Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword.

Authors:  Anthony M Battram; Mireia Bachiller; Beatriz Martín-Antonio
Journal:  Int J Mol Sci       Date:  2020-06-18       Impact factor: 5.923

Review 5.  Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets.

Authors:  Yungang Wang; Shouyan Deng; Jie Xu
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

6.  Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.

Authors:  Brie Chun; Joanna Pucilowska; ShuChing Chang; Isaac Kim; Benjamin Nikitin; Yoshinobu Koguchi; William L Redmond; Brady Bernard; Venkatesh Rajamanickam; Nathan Polaske; Paul A Fields; Valerie Conrad; Mark Schmidt; Walter J Urba; Alison K Conlin; Heather L McArthur; David B Page
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

Review 7.  Necroptosis in Immuno-Oncology and Cancer Immunotherapy.

Authors:  Jenny Sprooten; Pieter De Wijngaert; Isaure Vanmeerbeerk; Shaun Martin; Peter Vangheluwe; Susan Schlenner; Dmitri V Krysko; Jan B Parys; Geert Bultynck; Peter Vandenabeele; Abhishek D Garg
Journal:  Cells       Date:  2020-08-01       Impact factor: 6.600

8.  Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma.

Authors:  Alexandra Drakaki; Preet K Dhillon; Heather Wakelee; Stephen Y Chui; Jinjoo Shim; Matthew Kent; Viraj Degaonkar; Tien Hoang; Virginia McNally; Patricia Luhn; Ralf Gutzmer
Journal:  Oncoimmunology       Date:  2020-10-05       Impact factor: 8.110

9.  Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.

Authors:  Diana V Maslov; Karine Tawagi; Madhav Kc; Victoria Simenson; Helen Yuan; Cameron Parent; Adi Bamnolker; Richa Goel; Zoe Blake; Marc R Matrana; Daniel H Johnson
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

10.  Plasma Extracellular Vesicles Enhance HIV-1 Infection of Activated CD4+ T Cells and Promote the Activation of Latently Infected J-Lat10.6 Cells via miR-139-5p Transfer.

Authors:  Isobel Okoye; Lai Xu; Olaide Oyegbami; Shima Shahbaz; Desmond Pink; Priscilla Gao; Xuejun Sun; Shokrollah Elahi
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.